This study looks at infertility in women who are overweight or obese and are planning to undergo In Vitro Fertilization, which is a procedure where eggs are collected from the ovaries and fertilized with sperm in a laboratory to create embryos. The study will use Wegovy, which contains semaglutide, a medication that is given as an injection under the skin. Some women will receive semaglutide for 12 weeks before starting their fertility treatment, while others will not receive this pre-treatment. During the fertility procedure itself, all women will receive standard medications including ganirelix, which helps control the timing of egg release, follitropin alfa, which stimulates the ovaries to produce eggs, and triptorelin, which also helps regulate hormones during the treatment.
The purpose of this study is to find out whether treatment with semaglutide for 12 weeks before starting fertility treatment can improve the number of good quality embryos that develop to the blastocyst stage, which is an important stage of early embryo development that occurs about five to six days after fertilization. The study will compare results between women who receive semaglutide before their fertility treatment and those who do not receive this pre-treatment.
Women in the group receiving semaglutide will take this medication for 12 weeks before beginning their fertility treatment. After this period, all women will undergo the standard fertility treatment process where their ovaries are stimulated with medications to produce multiple eggs, the eggs are collected, fertilized in the laboratory, and the resulting embryos are observed as they develop and then frozen for future use. The study will track various aspects of embryo development using time-lapse monitoring, which allows continuous observation of how embryos grow and divide. The study will also measure changes in body weight, body mass index, and markers of ovarian function before and after the semaglutide treatment period.
Spain 
